CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 92 enrolled
Drug / intervention
clarithromycin +2 moredrug
Likely dose
clarithromycin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00318708
NCT00318708Phase 3Completed
CompareCT.gov

Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

Milton S. Hershey Medical Center·interventional·Posted Apr 27, 2006·Updated Mar 23, 2018

In Brief

A Phase 3 clinical trial evaluating clarithromycin, fluticasone propionate, and 1 other intervention for Asthma. Completed, enrolled 92 participants across 10 sites.

Detailed Summary

Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effectively treat asthma in these individuals. This study will evaluate the effectiveness of clarithromycin at controlling asthma symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 27, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.2 years ago

Interventions

clarithromycindrug

clarithromycin 500 mg twice daily (Biaxin)

fluticasone propionatedrug

fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)

placebo clarithromycindrug

placebo clarithromycin twice daily